Literature DB >> 21887822

Proteomic identification of Hsp70 as a new Plk1 substrate in arsenic trioxide-induced mitotically arrested cells.

Yu J Chen1, Ya-Ping Lin, Lu-Ping Chow, Te-Chang Lee.   

Abstract

We previously demonstrated that when arsenic trioxide (ATO)-induced mitotically arrested HeLa S3 cells (AIMACs) were treated with staurosporine (SSP) the cells rapidly exited mitosis. To better define the cellular targets and the underlying mechanisms of AIMACs, we applied 2-D DIGE followed by LC-MS/MS analysis and showed that SSP induced a significant change in the phosphoproteome of AIMACs. Among the proteins whose phosphorylation was modulated by SSP, we identified Hsp70, Rad 23B, and eukaryotic translation initiation factor 4B as potentially new substrates of polo-like kinase 1 (Plk1), an essential serine/threonine kinase with versatile mitotic functions. Since Hsp70 is a stress protein responsible for ATO treatment, we further identified Thr(13) , Ser(362) , Ser(631) , and Ser(633) on Hsp70 intracellularly phosphorylated in AIMACs by combining TiO(2) phospho-peptides enrichment and MS/MS analysis. Using antibody specifically against phosph-Ser(631) Hsp70 and further aided by expression of kinase-dead Plk1 and pharmacological inhibition of Plk1, we concluded that Ser(631) on Hsp70 is phosphorylated by Plk1 in AIMACs. By immnuofluorescent staining, we found the colocalization of Hsp70 and Plk1 in AIMACs but not in interphase cells. In addition, Plk1-mediated phosphorylation of Hsp70 prevented AIMACs from mitotic death. Our results reveal that Hsp70 is a novel substrate of Plk1 and that its phosphorylation contributes to attenuation of ATO-induced mitotic abnormalities.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21887822     DOI: 10.1002/pmic.201100329

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  8 in total

1.  Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer.

Authors:  Long Chen; Jie Li; Elia Farah; Sukumar Sarkar; Nihal Ahmad; Sanjay Gupta; James Larner; Xiaoqi Liu
Journal:  Mol Cancer Ther       Date:  2016-07-07       Impact factor: 6.261

2.  Low-dose arsenic-mediated metabolic shift is associated with activation of Polo-like kinase 1 (Plk1).

Authors:  Zhiguo Li; Ying Lu; Nihal Ahmad; Klaus Strebhardt; Xiaoqi Liu
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  Interleukin-1 Receptor Type 2 Acts with c-Fos to Enhance the Expression of Interleukin-6 and Vascular Endothelial Growth Factor A in Colon Cancer Cells and Induce Angiogenesis.

Authors:  Ai-Chung Mar; Chun-Ho Chu; Hui-Ju Lee; Chia-Wen Chien; Jing-Jy Cheng; Shung-Haur Yang; Jeng-Kai Jiang; Te-Chang Lee
Journal:  J Biol Chem       Date:  2015-07-24       Impact factor: 5.157

Review 4.  Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy.

Authors:  B T Gjertsen; P Schöffski
Journal:  Leukemia       Date:  2014-07-16       Impact factor: 11.528

Review 5.  Regulatory functional territory of PLK-1 and their substrates beyond mitosis.

Authors:  Shiv Kumar; Garima Sharma; Chiranjib Chakraborty; Ashish Ranjan Sharma; Jaebong Kim
Journal:  Oncotarget       Date:  2017-06-06

6.  HSP70 is required for the proper assembly of pericentriolar material and function of mitotic centrosomes.

Authors:  Chieh-Ting Fang; Hsiao-Hui Kuo; Shao-Chun Hsu; Ling-Huei Yih
Journal:  Cell Div       Date:  2019-05-10       Impact factor: 5.130

7.  The antitumor agent PBT-1 directly targets HSP90 and hnRNP A2/B1 and inhibits lung adenocarcinoma growth and metastasis.

Authors:  Chi-Yuan Chen; Shuenn-Chen Yang; Kuo-Hsiung Lee; Xiaoming Yang; Lin-Yi Wei; Lu-Ping Chow; Tzu-Chien V Wang; Tse-Ming Hong; Jau-Chen Lin; Crysline Kuan; Pan-Chyr Yang
Journal:  J Med Chem       Date:  2014-01-31       Impact factor: 7.446

8.  HSP70 regulates Eg5 distribution within the mitotic spindle and modulates the cytotoxicity of Eg5 inhibitors.

Authors:  Chieh-Ting Fang; Hsiao-Hui Kuo; Shao-Chun Hsu; Ling-Huei Yih
Journal:  Cell Death Dis       Date:  2020-09-01       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.